10 Apr PDE5i for ED and Survival in Men with Coronary Artery Disease
MedicalResearch.com Interview with:
Martin J Holzmann MD PhD
Department of Emergency Medicine
Karolinska University Hospital
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We published a paper 2007 in Heart where we showed that PDE5i lower mortality in men with a recent myocardial infarction. With this study we wanted to investigate if PDE5i led to a beneficial outcome in men with stable coronary artery disease.
MedicalResearch.com: What should readers take away from your report?
Response: Clinicians who meet men with coronary artery disease should raise the question of erectile dysfunction. If there is any indication of ED the patient should be prescribed a PDE5i.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: In order to answer the question if PDE5i prolong life in men with CAD a RCT is needed.
I received consultancy honoraria from Idorsia.
MedicalResearch.com Editors’ Note: PDE5i drugs are used to treat erectile dysfunction.
Daniel P. Andersson, Laura Landucci, Ylva Trolle Lagerros, Alessandra Grotta, Rino Bellocco, Mikael Lehtihet, Martin J. Holzmann,
Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease,
Journal of the American College of Cardiology,
Volume 77, Issue 12, 2021, Pages 1535-1550, ISSN 0735-1097,
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on April 10, 2021 by Marie Benz MD FAAD